Skip to Main Content

Rise and shine, everyone, another steamy day is on the way. Yes, a heat wave continues to envelop the Pharmalot campus, where the shortest person is sleeping in and the official mascots are already exhausted. As for us, we are quaffing cups of stimulation and revving up the cooling machine. There is, after all, a lot to be done. So time to get cracking. Here are some tidbits. Hope your day is productive …

An execution drug obtained by Arkansas prison officials earlier this month appears to have been made by a Pfizer subsidiary, even though the drug maker said it doesn’t want its medicines used for executions, the Associated Press reports. The sale of vecuronium bromide by an unknown third party illustrates how difficult it can be for companies to prevent such sales in states like Arkansas that have execution secrecy laws.

Kadmon, a biotech started by Sam Waksal, plans to raise $100 million in a public offering this week, despite a leaky balance sheet and the notoriety of its founder, STAT tells us. Waksal, you may recall, scaled biotech heights thanks to the Erbitux cancer treatment marketed by one of his previous ventures, ImClone Systems. But he was later convicted in an infamous insider trading case that also ensnared one of his pals, television show host Martha Stewart.


A decade ago, Barr Pharmaceutical flew Tim Kaine, who was then Virginia governor and is now Hillary Clinton’s running mate, to a meeting in Aspen on a private jet, the New York Times reports. This occurred just as Barr, which is owned by Teva, was lobbying Kaine to write a letter to the Food and Drug Administration on its behalf. And he signed the letter before taking the flight, which records show was worth about $12,000.

Celgene said its Revlimid drug failed to extend survival as a maintenance therapy for a type of blood cancer after patients responded to prior treatment, Reuters reports. As a result, the biotech will not seek an additional approval for Revlimid, a multiple myleoma treatment that generates about $6 billion in annual sales for that use. Celgene stock fell more than 2 percent.


Boehringer Ingelheim has stopped two Phase 3 trials for its Gilotrif lung cancer drug after a data monitoring committee determined the treatment was no better than placebo, PharmaTimes tells us.

Sandoz is repeating bioequivalence studies and Teva Pharmaceutical is withdrawing an antimalarial after European regulators recommended suspending drugs tested by Semler Research, InPharma Technologist says.

European regulators delayed permanent approval of a PTC Therapeutics’s Duchenne muscular dystrophy drug, and the company may submit a new study in response, TheStreet reports.

A New Jersey appeals court overturned a pair of $9 million verdicts against Roche that had been awarded to users of Accutane who claimed they developed ulcerative colitis after taking the drug, the New Jersey Law Journal writes.

A Johnson & Johnson lab is being used as an incubator in which some companies are funded by other drug makers, Fortune writes.

Germany wants to extend a price cut for drugs covered by statutory health insurance for five years beyond 2017 and also wants to lower prices of newly launched drugs if sales exceed a certain threshold, Reuters says.

India has rejected as many as 955 patent applications in the pharmaceutical sector in the last three years, according to the Economic Times.

Comments are closed.